Skip to content
Research Monograph

Sermorelin Acetate (GRF 1-29 NH₂)

Also Known AsGRF(1-29)NH₂ · GHRH(1-29) · Geref · Sermorelin acetate · Growth Hormone Releasing Factor 1-29

Molecular Weight3357.93 g/mol
Discovered1982
Citations5 peer-reviewed
Research Areas5 domains
Background

Sermorelin is the synthetic 29-amino-acid fragment (1-29) of human growth hormone-releasing hormone (GHRH, 44 amino acids), representing the shortest fully functional GHRH fragment. GHRH was first isolated from a pancreatic tumor in 1982 independently by Roger Guillemin and Wylie Vale. Sermorelin (GRF 1-29) was developed for clinical use and FDA-approved in 1997 (as Geref) for diagnosis and treatment of growth hormone deficiency in children.

Amino Acid SequenceTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Mechanisms of Action

How Sermorelin Works

01

GHRH Receptor Agonism

Sermorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, a Gs-coupled GPCR that activates adenylyl cyclase. The resulting cAMP increase activates PKA, which opens voltage-gated calcium channels and stimulates both GH gene transcription and GH granule exocytosis. This preserves the natural pulsatile GH secretion pattern.

GHRHRadenylyl cyclasecAMP/PKApituitary somatotrophs
02

Pulsatile GH Release with Negative Feedback

Unlike exogenous GH administration, sermorelin stimulates endogenous GH release subject to normal hypothalamic-pituitary feedback. Somatostatin (SST) and IGF-1 negative feedback loops remain intact, preventing supraphysiological GH levels and preserving the ultradian GH pulse pattern critical for downstream signaling specificity.

somatostatin feedbackIGF-1 negative feedbackGH pulsatility
03

IGF-1 Axis Activation

GH released by sermorelin stimulation acts on hepatic GH receptors to stimulate IGF-1 synthesis and secretion. IGF-1 mediates the majority of GH's anabolic, growth-promoting, and metabolic effects through IGF-1R activation of PI3K/Akt and MAPK/ERK signaling in target tissues (muscle, bone, cartilage, liver).

hepatic GH receptorIGF-1IGF-1RPI3K/AktMAPK/ERK
Evidence-Graded Research Areas

Published Research

Strong
Moderate
Emerging
Preclinical

Age-Related GH Decline (Somatopause)

Strong

GH secretion declines approximately 14% per decade after age 25 ('somatopause'). Sermorelin has been studied as a physiological approach to restoring GH pulsatility in aging populations. Clinical studies demonstrate increased IGF-1 levels, improved body composition (decreased fat mass, increased lean mass), and improved sleep quality in GH-deficient adults.

Pediatric Growth Hormone Deficiency

Strong

Sermorelin was FDA-approved (Geref) for diagnosis and treatment of idiopathic GH deficiency in children. Clinical trials demonstrated significant increases in growth velocity, predicted adult height, and IGF-1 levels. Sermorelin testing (GHRH stimulation test) remains a standard diagnostic tool for distinguishing pituitary from hypothalamic causes of GH deficiency.

Body Composition & Metabolism

Moderate

Studies in obese and aging adults demonstrate that sermorelin increases GH pulse amplitude, reduces visceral adiposity, and improves insulin sensitivity. The preservation of pulsatile GH release (vs. continuous GH exposure) is important because pulsatile GH preferentially activates lipolytic pathways while continuous GH exposure promotes lipogenesis.

Sleep Architecture

Moderate

GH secretion is closely coupled to slow-wave sleep (SWS). GHRH administration increases SWS duration and EEG delta power in both young and elderly subjects. Sermorelin given at bedtime enhances the natural nocturnal GH surge, potentially improving sleep quality and restorative sleep metrics.

Cardiac Function

Preclinical

GH/IGF-1 signaling has trophic effects on cardiomyocytes. Preclinical studies of GHRH analogs show improved cardiac function in models of heart failure, myocardial infarction, and dilated cardiomyopathy. GHRH receptors are expressed on cardiomyocytes, suggesting direct cardiac effects independent of circulating GH/IGF-1.

Safety Profile

Sermorelin has extensive clinical safety data from its FDA-approved use (Geref). Adverse effects are generally mild: injection site reactions (pain, redness, swelling), facial flushing, headache, and transient dizziness. Because sermorelin works through the natural GHRH receptor and is subject to somatostatin negative feedback, the risk of GH excess is inherently limited — the pituitary has a ceiling on GH release capacity. Antibody formation has been reported in a minority of long-term users but rarely impacts efficacy.

Handling & Storage

Reconstitute with bacteriostatic water provided. Direct gentle stream along vial wall — do not shake. Store reconstituted solution at 2-8°C and use within 14 days. Lyophilized powder stable at -20°C for 24+ months. Sermorelin contains a methionine residue (position 27) susceptible to oxidation — minimize air exposure and protect from light.

References & Citations

Peer-Reviewed Literature

  1. 1

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

    Walker RF.

    Clinical Interventions in Aging, 2006PubMed 18046911
  2. 2

    Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men

    Vittone J, Blackman MR, Busby-Whitehead J, et al.

    Metabolism, 1997PubMed 9109836DOI
  3. 3

    Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men

    Corpas E, Harman SM, Pineyro MA, et al.

    Journal of Clinical Endocrinology and Metabolism, 1992PubMed 1487077DOI
  4. 4

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

    Ionescu M, Frohman LA.

    Journal of Clinical Endocrinology and Metabolism, 2006PubMed 16940448DOI
  5. 5

    Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice

    Steyn FJ, Tober JN, Ngo ST, et al.

    Endocrinology, 2013PubMed 23592752DOI
Frequently Asked Questions

Sermorelin FAQ

What is Sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide identical to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It is the shortest GHRH fragment that retains full biological activity. It was FDA-approved (as Geref) for diagnosing and treating pediatric growth hormone deficiency. Sermorelin stimulates the pituitary to produce and release GH through the natural GHRH receptor.

How does Sermorelin differ from exogenous GH?

Exogenous GH bypasses the pituitary entirely, delivering a flat bolus that disrupts natural pulsatile GH patterns and suppresses endogenous production via IGF-1 feedback. Sermorelin stimulates the pituitary to release its own GH, preserving pulsatile secretion and negative feedback control. This makes supraphysiological GH levels unlikely and maintains the ultradian rhythm critical for tissue-specific GH signaling.

What is the difference between Sermorelin and CJC-1295?

Both are GHRH analogs that bind the GHRH receptor. Sermorelin is identical to native GHRH(1-29) with a short half-life (~12 minutes), producing acute GH pulses. CJC-1295 (with DAC) has amino acid substitutions and a Drug Affinity Complex that extends its half-life to ~8 days via albumin binding. Sermorelin more closely mimics natural GH pulsatility while CJC-1295 provides sustained GHRH receptor stimulation.

How should Sermorelin be stored?

Lyophilized Sermorelin should be stored at -20°C for long-term stability (24+ months). Once reconstituted with bacteriostatic water, store at 2-8°C and use within 14 days. Protect from light. The methionine residue at position 27 is susceptible to oxidation — minimize repeated air exposure.

Was Sermorelin FDA approved?

Yes. Sermorelin acetate (brand name Geref) was FDA-approved in 1997 for the treatment of idiopathic growth hormone deficiency in children and as a diagnostic tool (GHRH stimulation test). EMD Serono discontinued the branded product in 2008 for commercial reasons, not safety concerns. Sermorelin remains available through compounding pharmacies.

Available for Research

Sermorelin Products

All compounds 99%+ purity, verified by Janoshik Analytical. GMP-manufactured lyophilized powder.

Buy 3, Save 30%
Ser
Lyophilized Powder
99%

The gentle GH booster — stimulates your pituitary to produce its own growth hormone naturally, improving muscle tone, fat loss, sleep quality, and recovery.

  • Stimulates your body's own growth hormone production naturally
  • Improves body composition — more muscle, less fat
$47.99
Related Compounds

Explore Related Research

Buy 3, Save 30%
CJC
Lyophilized Powder
99%

Amplifies your natural growth hormone pulses — builds lean muscle, burns fat, deepens sleep, and makes your skin look younger.

  • Boosts natural growth hormone for muscle building and fat loss
  • Improves deep sleep quality and recovery
$60.99
Buy 3, Save 30%bestseller
CJC
Lyophilized Powder
99%
Blend

The king of growth hormone stacks — packs on lean muscle, strips fat, deepens sleep, and tightens skin without the cortisol spike or hunger.

  • The gold standard GH stack — maximum muscle growth and fat loss
  • Deep, restorative sleep from the first use
$156.99
Buy 3, Save 30%bestseller
Ipa
Lyophilized Powder
99%

The cleanest growth hormone booster — releases GH without the hunger, bloating, or cortisol crash of other peptides. Pure muscle-building, fat-burning signal.

  • Clean growth hormone release without hunger spikes or cortisol
  • Builds lean muscle and accelerates fat burning
$89.99
Buy 3, Save 30%
GHR
Lyophilized Powder
99%

The mass-builder's GH peptide — triggers the strongest growth hormone release available, drives appetite for serious bulking, and protects joints under heavy loads.

  • Strongest growth hormone release of any GH peptide
  • Dramatically increases appetite — ideal for building mass
$65.00

Disclaimer: This monograph is provided for educational and research purposes only. G26x Peptides products are sold exclusively as research chemicals. They are not intended for human consumption, therapeutic use, or as dietary supplements. All research should be conducted in compliance with applicable laws and institutional review board protocols. Information presented here is sourced from published peer-reviewed literature and does not constitute medical advice.